Fatty Liver Disease Drugs Market Size, Share & Industry Analysis, By Product (Rezdiffra (Resmetirom), Wegovy (Semaglutide), and Others), By Drug Class (THR-beta Agonist, GLP-1 Receptor Agonist, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Specialty Pharmacies & Others), and Regional Forecast, 2026-2034

Last Updated: April 24, 2026 | Format: PDF | Report ID: FBI116006

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2021-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2021-2024
Growth Rate	CAGR of 24.24% from 2026-2034
Unit	Value (USD Million)
Segmentation	By Product, Drug Class, Route of Administration, Distribution Channel, and Region
By Product	Rezdiffra (Resmetirom) Wegovy (Semaglutide) Others
By Drug Class	THR-beta Agonist GLP-1 Receptor Agonist Others
By Route of Administration	Oral Parenteral
By Distribution Channel	Hospital Pharmacies Retail Pharmacies & Drug Stores Specialty Pharmacies & Others
By Region	North America (By Product, Drug Class, Route of Administration, Distribution Channel, and Country) U.S. Canada Europe (By Product, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region) Germany U.K. France Spain Italy Rest of Europe Asia Pacific (By Product, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region) China Japan India Australia Rest of Asia Pacific Rest of the World (By Product, Drug Class, Route of Administration, and Distribution Channel)